TrialThoracic cancer2016

Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.

Yanzhe Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.